Key facts
- This page summarizes Dipchand Nishar's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 May 2021, 16:45.
Dipchand Nishar - 21 May 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- Director
- Issuer ticker
- VIR
- Reported as of
- 21 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 May 2021, 16:45:09 UTC
- Next SEC filing
- 25 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Howard Horn, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dipchand Nishar filed Form 4 for Vir Biotechnology, Inc. (VIR) on 25 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,374
- Change %
- Price
- $0.000000
- Shares after
- 3,374
- Date
- 21 May 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,748
- Change %
- Price
- $0.000000
- Shares after
- 6,748
- Date
- 21 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,748
- Exercise price
- $45.28
* marks a reported price that did not pass the local price check.